Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over. World J Hepatol 2020; 12(9): 672-684 [PMID: 33033572 DOI: 10.4254/wjh.v12.i9.672]
Corresponding Author of This Article
Hideyuki Tamai, MD, PhD, Director, Department of Hepatology, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama 6408505, Japan. hdy-tamai@wakayamah.johas.go.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dose reduction or interruption of ribavirin due to anemia2
32 (13.2%)
18 (21.7%)
14 (7.7%)
0.002
Dermatitis
9 (3.4%)
1 (1.2%)
8 (4.4%)
0.281
Depression
3 (1.1%)
1 (1.2%)
2 (0.5%)
1.000
Headache
4 (1.5%)
0
4 (2.2%)
0.313
Infection
4 (1.5%)
1 (1.2%)
3 (1.6%)
1.000
Other adverse events
11 (4.2%)
5 (6.0%)
6 (3.3%)
0.328
Elevated bilirubin level
2 (0.8%)
1 (1.2%)
1 (0.5%)
0.529
Elevated transaminase level
4 (1.5%)
2 (2.4%)
2 (1.1%)
0.592
Elevated serum ammonia level
5 (1.9%)
2 (2.4%)
3 (1.6%)
0.650
Elevated uric acid level
26 (9.8%)
10 (12.0%)
16 (8.8%)
0.504
Citation: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over. World J Hepatol 2020; 12(9): 672-684